GlucoTrack, Inc. (GCTK)
USD 0.23
(-5.78%)
USD 0.23
(-5.78%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.29 Million USD | -102.93% |
| 2022 | -2.11 Million USD | 63.58% |
| 2021 | -5.81 Million USD | 38.56% |
| 2020 | -9.46 Million USD | -22960.23% |
| 2019 | -41.02 Thousand USD | -157.66% |
| 2018 | 71.14 Thousand USD | -44.84% |
| 2017 | 128.98 Thousand USD | 877.31% |
| 2016 | 13.19 Thousand USD | 102.94% |
| 2015 | -448.38 Thousand USD | 91.39% |
| 2014 | -5.2 Million USD | -207.75% |
| 2013 | -1.69 Million USD | -234.56% |
| 2012 | -505.98 Thousand USD | 60.79% |
| 2011 | -1.29 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 115 Thousand USD | 109.39% |
| 2024 Q1 | -1.22 Million USD | 71.49% |
| 2023 Q4 | -4.29 Million USD | 35.92% |
| 2023 Q2 | -8.58 Million USD | -959.88% |
| 2023 FY | -4.29 Million USD | -102.93% |
| 2023 Q3 | -6.7 Million USD | 21.91% |
| 2023 Q1 | -810 Thousand USD | 61.74% |
| 2022 Q2 | -3.66 Million USD | 19.78% |
| 2022 Q3 | -3.05 Million USD | 16.71% |
| 2022 Q4 | -2.11 Million USD | 30.59% |
| 2022 FY | -2.11 Million USD | 63.58% |
| 2022 Q1 | -4.56 Million USD | 21.46% |
| 2021 Q3 | -6.73 Million USD | 11.34% |
| 2021 Q4 | -5.81 Million USD | 13.69% |
| 2021 Q1 | -8.54 Million USD | 9.66% |
| 2021 FY | -5.81 Million USD | 38.56% |
| 2021 Q2 | -7.59 Million USD | 11.13% |
| 2020 Q4 | -9.46 Million USD | 8.71% |
| 2020 Q1 | -12.08 Million USD | -29366.72% |
| 2020 FY | -9.46 Million USD | -22960.23% |
| 2020 Q2 | -11.2 Million USD | 7.27% |
| 2020 Q3 | -10.36 Million USD | 7.55% |
| 2019 FY | -41.02 Thousand USD | -157.66% |
| 2019 Q1 | 341.86 Thousand USD | 380.54% |
| 2019 Q3 | -888.3 Thousand USD | 53.8% |
| 2019 Q4 | -41.02 Thousand USD | 95.38% |
| 2019 Q2 | -1.92 Million USD | -662.39% |
| 2018 FY | 71.14 Thousand USD | -44.84% |
| 2018 Q4 | 71.14 Thousand USD | 109.26% |
| 2018 Q3 | -768.38 Thousand USD | -597.81% |
| 2018 Q2 | 154.35 Thousand USD | 214.37% |
| 2018 Q1 | -134.96 Thousand USD | -204.64% |
| 2017 Q1 | -1.46 Million USD | -11229.36% |
| 2017 Q2 | -954.43 Thousand USD | 35.02% |
| 2017 FY | 128.98 Thousand USD | 877.31% |
| 2017 Q3 | -284.83 Thousand USD | 70.16% |
| 2017 Q4 | 128.98 Thousand USD | 145.28% |
| 2016 Q3 | -529.7 Thousand USD | 57.4% |
| 2016 FY | 13.19 Thousand USD | 102.94% |
| 2016 Q4 | 13.19 Thousand USD | 102.49% |
| 2016 Q2 | -1.24 Million USD | -1104.81% |
| 2016 Q1 | -103.21 Thousand USD | 76.98% |
| 2015 Q4 | -448.38 Thousand USD | 76.94% |
| 2015 FY | -448.38 Thousand USD | 91.39% |
| 2015 Q3 | -1.94 Million USD | 41.95% |
| 2015 Q2 | -3.34 Million USD | 26.21% |
| 2015 Q1 | -4.53 Million USD | 12.87% |
| 2014 Q4 | -5.2 Million USD | -39.43% |
| 2014 Q1 | -1.59 Million USD | 5.88% |
| 2014 Q2 | 108.63 Thousand USD | 106.82% |
| 2014 FY | -5.2 Million USD | -207.75% |
| 2014 Q3 | -3.73 Million USD | -3539.16% |
| 2013 Q3 | -2.83 Million USD | 22.5% |
| 2013 Q2 | -3.65 Million USD | 21.87% |
| 2013 Q4 | -1.69 Million USD | 40.31% |
| 2013 Q1 | -4.68 Million USD | -825.58% |
| 2013 FY | -1.69 Million USD | -234.56% |
| 2012 Q3 | 422.17 Thousand USD | 360.11% |
| 2012 Q1 | -790.28 Thousand USD | 38.75% |
| 2012 Q2 | -162.3 Thousand USD | 79.46% |
| 2012 FY | -505.98 Thousand USD | 60.79% |
| 2012 Q4 | -505.98 Thousand USD | -219.85% |
| 2011 Q4 | -1.29 Million USD | 30.26% |
| 2011 FY | -1.29 Million USD | 0.0% |
| 2011 Q3 | -1.85 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 2.58 Million USD | 266.447% |
| AngioDynamics, Inc. | -70.14 Million USD | 93.875% |
| AtriCure, Inc. | -9.81 Million USD | 56.235% |
| Avinger, Inc. | 10.12 Million USD | 142.451% |
| Azenta, Inc. | -618.47 Million USD | 99.305% |
| BioLife Solutions, Inc. | 7.25 Million USD | 159.231% |
| The Cooper Companies, Inc. | 2.44 Billion USD | 100.175% |
| Daxor Corporation | 755.65 Thousand USD | 668.51% |
| Ekso Bionics Holdings, Inc. | -1.47 Million USD | -192.245% |
| Femasys Inc. | -15.01 Million USD | 71.389% |
| Harvard Bioscience, Inc. | 38.49 Million USD | 111.161% |
| Hologic, Inc. | 374.4 Million USD | 101.147% |
| ICU Medical, Inc. | 1.45 Billion USD | 100.296% |
| Intuitive Surgical, Inc. | -2.66 Billion USD | 99.839% |
| KORU Medical Systems, Inc. | -7.03 Million USD | 38.952% |
| LeMaitre Vascular, Inc. | -5.17 Million USD | 16.969% |
| Innovative Eyewear, Inc. | -4.28 Million USD | -0.199% |
| Innovative Eyewear, Inc. | -4.28 Million USD | -0.199% |
| Masimo Corporation | 804 Million USD | 100.534% |
| Microbot Medical Inc. | -2.28 Million USD | -87.927% |
| Meihua International Medical Technologies Co., Ltd. | -9.59 Million USD | 55.23% |
| Merit Medical Systems, Inc. | 302.22 Million USD | 101.421% |
| Nephros, Inc. | -2.47 Million USD | -73.857% |
| NovoCure Limited | 355.42 Million USD | 101.209% |
| NEXGEL, Inc. | 98 Thousand USD | 4483.673% |
| NEXGEL, Inc. | 98 Thousand USD | 4483.673% |
| Singular Genomics Systems, Inc. | 59.05 Million USD | 107.275% |
| OraSure Technologies, Inc. | -276.9 Million USD | 98.449% |
| Pro-Dex, Inc. | 10.91 Million USD | 139.355% |
| Pulse Biosciences, Inc. | -35.22 Million USD | 87.803% |
| Predictive Oncology Inc. | -5.87 Million USD | 26.837% |
| Precision Optics Corporation, Inc. | 3.02 Million USD | 241.82% |
| QuidelOrtho Corporation | 2.49 Billion USD | 100.172% |
| Repligen Corporation | -39.51 Million USD | 89.129% |
| Sanara MedTech Inc. | 6.64 Million USD | 164.651% |
| STAAR Surgical Company | -147.2 Million USD | 97.082% |
| Sharps Technology, Inc. | -3.01 Million USD | -42.586% |
| Utah Medical Products, Inc. | -92.52 Million USD | 95.357% |
| DENTSPLY SIRONA Inc. | 1.96 Billion USD | 100.219% |
| Jin Medical International Ltd. | -2.81 Million USD | -52.529% |